Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golexanolone in primary biliary cholangitis with fatigue and cognitive dysfunction
2024-515907-20-00Phase 2Completed
- Sponsor
- Umecrine Cognition
- Start
- Sep 2022
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of golexanolone in primary biliary cholangitis (PBC) (3 arms), sponsored by Umecrine Cognition. Primary endpoints: Part A safety and tolerability and Part B safety and tolerability. Started Sep 2022; status: completed.
02
Drugs
golexanolone
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2024-515907-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515907-20-00.